fbpx
01 / 05
1,000 Bits of Good News You May Have Missed in 2023

Blog Post | Human Development

1,000 Bits of Good News You May Have Missed in 2023

A necessary balance to the torrent of negativity.

Reading the news can leave you depressed and misinformed. It’s partisan, shallow, and, above all, hopelessly negative. As Steven Pinker from Harvard University quipped, “The news is a nonrandom sample of the worst events happening on the planet on a given day.”

So, why does Human Progress feature so many news items? And why did I compile them in this giant list? Here are a few reasons:

  • Negative headlines get more clicks. Promoting positive stories provides a necessary balance to the torrent of negativity.
  • Statistics are vital to a proper understanding of the world, but many find anecdotes more compelling.
  • Many people acknowledge humanity’s progress compared to the past but remain unreasonably pessimistic about the present—not to mention the future. Positive news can help improve their state of mind.
  • We have agency to make the world better. It is appropriate to recognize and be grateful for those who do.

Below is a nonrandom sample (n = ~1000) of positive news we collected this year, separated by topic area. Please scroll, skim, and click. Or—to be even more enlightened—read this blog post and then look through our collection of long-term trends and datasets.

Agriculture

Aquaculture

Farming robots and drones

Food abundance

Genetic modification

Indoor farming

Lab-grown produce

Pollination

Other innovations

Conservation and Biodiversity

Big cats

Birds

Turtles

Whales

Other comebacks

Forests

Reefs

Rivers and lakes

Surveillance and discovery

Rewilding and conservation

De-extinction

Culture and tolerance

Gender equality

General wellbeing

LGBT

Treatment of animals

Energy and natural Resources

Fission

Fusion

Fossil fuels

Other energy

Recycling and resource efficiency

Resource abundance

Environment and pollution

Climate change

Disaster resilience

Air pollution

Water pollution

Growth and development

Education

Economic growth

Housing and urbanization

Labor and employment

Health

Cancer

Disability and assistive technology

Dementia and Alzheimer’s

Diabetes

Heart disease and stroke

Other non-communicable diseases

HIV/AIDS

Malaria

Other communicable diseases

Maternal care

Fertility and birth control

Mental health and addiction

Weight and nutrition

Longevity and mortality 

Surgery and emergency medicine

Measurement and imaging

Health systems

Other innovations

Freedom

    Technology 

    Artificial intelligence

    Communications

    Computing

    Construction and manufacturing

    Drones

    Robotics and automation

    Autonomous vehicles

    Transportation

    Other innovations

    Science

    AI in science

    Biology

    Chemistry and materials

      Physics

      Space

      Violence

      Crime

      War

      World Health Organization | Communicable Disease

      Visceral Leishmaniasis Drug Enters Phase II Trial in Ethiopia

      “Also known as kala-azar, visceral leishmaniasis is the world’s deadliest parasitic killer after malaria.

      It causes fever, weight loss, spleen and liver enlargement, and, if not treated, death. Kala-azar is transmitted by the bite of infected sandflies and is endemic in 80 countries, mainly in Eastern Africa, South Asia, and Latin America. One billion people are at risk globally and Eastern Africa has currently the highest number of cases. As for other vector-borne diseases, climate change is changing the epidemiology of leishmaniasis and could lead to its expansion to new areas. An estimated 50,000 to 90,000 new cases occur worldwide annually, and half are children under 15 years of age.

      In Africa, the current treatment for visceral leishmaniasis includes painful injections given at hospital daily for 17 days, a treatment that may also present rare but life-threatening side effects, including to the heart, liver, and pancreas. In contrast, the new molecule under study in Ethiopia, called LXE408, is administered in the form of oral pills and is expected to be safer than the current treatment.”

      From World Health Organization.

      Financial Times | Communicable Disease

      EU Approves New Antibiotic to Tackle Rise of Superbugs

      “The EU has approved a new antibiotic for serious illnesses such as pneumonia and urinary tract infections, marking a step forward in the drive to combat the growing resistance of “superbugs” to existing drugs.

      Emblaveo, marketed in Europe by US pharmaceutical company Pfizer, combines two existing medicines to tackle so-called Gram-negative bacteria that are among the leading drug-resistance threats.”

      From Financial Times.

      Reuters | Vaccination

      Nigeria Becomes First Country to Roll out New Meningitis Vaccine

      “Nigeria has become the first country in the world to roll out the “revolutionary” new Men5CV vaccine against meningitis, the World Health Organization (WHO) said…

      The new vaccine is reported to protect against the five major strains of the disease that are prevalent in Nigeria, unlike the initial vaccine that works against only one strain, said the WHO.”

      From Reuters.

      NBC News | Vaccination

      Chlamydia Vaccine Shows Promise in Early Trial

      “An early-stage clinical trial yielded promising results for a chlamydia vaccine, researchers reported Thursday in The Lancet Infectious Diseases. 

      There is currently no vaccine to protect against the sexually transmitted infection, which is the most common bacterial STI in the United States…

      The phase 1 clinical trial, led by researchers in the United Kingdom and Denmark, found that the experimental vaccine was safe and induced an immune response.”

      From NBC News.